- Molecular NameEthosuximide
- SynonymAethosuximide; Ethosuccimide; Ethosuccinimide; Ethosuxide; Etosuximida
- Weight141.17
- Drugbank_IDDB00593
- ACS_NO77-67-8
- Show 3D model
- LogP (experiment)0.38
- LogP (predicted, AB/LogP v2.0)0.4
- pka9.3
- LogD (pH=7, predicted)0.4
- Solubility (experiment)222 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.54
- LogSw (predicted, AB/LogsW2.0)86.46
- Sw (mg/ml) (predicted, ACD/Labs)40.97
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds1
- TPSA46.17
- StatusFDA approved
- AdministrationN/A
- PharmacologyA succinimide anticonvulsant, used mainly in absence seizures.
- Absorption_valueN/A
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- Bioavailability93.0
- Protein binding0.0
- Volume of distribution (VD)0.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic (CYP3A4, CYP2E1). Metabolised by hydroxylation to 3-hydroxyethosuximide and 1-hydroxyethylethosuximide; the latter is further oxidised to produce 2-acetyl-2-methylsuccinimide; an additional metabolite, 2-carboxymethyl-2-methylsuccinimide has also been reported. None of the metabolites is pharmacologically active.
- Half life40~60 h in adults and about 30 h in children.
- ExcretionAbout 25% of a dose is excreted in the urine in 24 h as 1-hydroxyethylethosuximide glucuronide and about 14% as the unconjugated metabolite. Up to about 20% of a dose is excreted as unchanged drug in the urine over a 9 day period.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe estimated minimum lethal dose is 5 g. Toxic effects may be observed at plasma concentrations greater than about 100 mg/L.
- LD50 (rat)N/A
- LD50 (mouse)N/A